Deferiprone
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1999
- First approval year
- 1999
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Deferiprone
- Molecular weight
- 139.15
- Structure (SMILES)
- Cc1c(O)c(=O)ccn1C
- deferiprone lipomed
- Deferiprone lipomed
- ferriprox
- Ferriprox
- apo 066
- apo 66
- APO-066
- APO-66
- cp 20
- CP-20
- cp20
- CP20
- deferasirox and deferiprone
- deferipron
- Deferipron
- deferiprona
- Deferiprona
- deferiprone
- Deferiprone
- Deferiprone (DFP)
- Deferiprone (L1)
- DEFERIPRONE [EMA EPAR]
- DEFERIPRONE [EP MONOGRAPH]
- deferiprone [INN]
- DEFERIPRONE [MART.]
- DEFERIPRONE [MI]
- DEFERIPRONE [ORANGE BOOK]
- DEFERIPRONE [USAN]
- DEFERIPRONE [VANDF]
And 40 more, listed on the interactive page.
- ATC classification codes
- V03AC02
Sources for recorded values
- CAS registry numbers
- 30652-11-0
- ChEMBL ID
- CHEMBL70927
- InChIKey
- TZXKOCQBRNJULO-UHFFFAOYSA-N
- PubChem compound IDs
- 2972
- RxNorm IDs (RxCUI)
- 11645
- FDA ingredient codes (UNII)
- 2BTY8KH53L
- Applicant
- CHIESI
- Approval date
- 14 Oct 2011
- Application number
- NDA021825
- Status
- Authorised
- Status date
- 25 Aug 1999
- Authorisation date
- 25 Aug 1999
- Approved indications
- Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate. Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction.
- Product number
- EMEA/H/C/000236
- Authorisation holder
- Chiesi Farmaceutici S.p.A.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 1
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- beta-Thalassemia
- Iron Overload
European medicines record
- Patents
- 7
- Designations
- 3
- Earliest recorded loss of exclusivity
- 25 Oct 2038
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- deferiprone
- Type
- Synthetic organic
- Drug name stem
- -iprone
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Myocardial Infarction
- Highest recorded phase
- 1
- Condition identifier
- EFO:0008583
- Subject identifier
- D009203
- Condition
- Hemochromatosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1000642
- Subject identifier
- D006432
- Condition
- Iron Overload
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000642
- Subject identifier
- D019190
- Condition
- Thalassemia
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001996
- Subject identifier
- D013789
- Condition
- Acute Kidney Injury
- Highest recorded phase
- 3
- Condition identifier
- HP:0001919
- Subject identifier
- D058186
- Condition
- Cognitive Dysfunction
- Highest recorded phase
- 0.5
- Condition identifier
- HP:0100543
- Subject identifier
- D060825
- Condition
- Amyotrophic Lateral Sclerosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004976
- Subject identifier
- D000690
- Condition
- Parkinson Disease
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
- Condition
- Pantothenate Kinase-Associated Neurodegeneration
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0009319
- Subject identifier
- D006211
- Condition
- Anemia, Sickle Cell
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0011382
- Subject identifier
- D000755
- Condition
- Cerebellar Ataxia
- Highest recorded phase
- 0.5
- Condition identifier
- MONDO:0011426
- Subject identifier
- D002524
- Condition
- beta-Thalassemia
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0016486
- Subject identifier
- D017086
- Condition
- Friedreich Ataxia
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100339
- Subject identifier
- D005621
- Condition
- beta-Thalassemia
- Highest recorded phase
- 4
- Condition identifier
- Orphanet:848
- Subject identifier
- D017086
- Condition identifier
- EFO_0000712
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0008583
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000642
- Condition identifier
- EFO_1001996
- Condition identifier
- HP_0100543
- Highest recorded phase
- 1
- Condition identifier
- HP_0100543
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0000984
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004975
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004976
- Condition identifier
- MONDO_0004976
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005015
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005068
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005149
- Condition identifier
- MONDO_0005180
- Condition identifier
- MONDO_0005180
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005267
- Condition identifier
- MONDO_0005272
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009319
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011382
- Condition identifier
- MONDO_0011382
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0011426
And 13 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
- Effect
- hematological toxicity
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Event
- agranulocytosis
- Reports
- 105
- Reporting signal score
- 374.029
- Event
- haemoglobin decreased
- Reports
- 24
- Reporting signal score
- 17.61
- Event
- liver function test increased
- Reports
- 10
- Reporting signal score
- 13.4045
- Event
- liver iron concentration increased
- Reports
- 2
- Reporting signal score
- 10.4511
- Event
- model for end stage liver disease score abnormal
- Reports
- 2
- Reporting signal score
- 13.3587
- Event
- neutropenia
- Reports
- 78
- Reporting signal score
- 116.776
- Event
- neutrophil count decreased
- Reports
- 20
- Reporting signal score
- 27.6333
- Event
- pyrexia
- Reports
- 45
- Reporting signal score
- 19.9874
- Event
- rash
- Reports
- 3
- Reporting signal score
- 9.06274
- Event
- renal impairment
- Reports
- 16
- Reporting signal score
- 10.9596
- Event
- sepsis
- Reports
- 17
- Reporting signal score
- 13.6136
- Event
- serum ferritin decreased
- Reports
- 4
- Reporting signal score
- 12.0678
- Event
- serum ferritin increased
- Reports
- 9
- Reporting signal score
- 22.9429
- Event
- sickle cell anaemia with crisis
- Reports
- 36
- Reporting signal score
- 159.381
- Event
- vitamin c deficiency
- Reports
- 2
- Reporting signal score
- 9.54062
- Event
- white blood cell count decreased
- Reports
- 37
- Reporting signal score
- 42.0776
- NCT00103753
- NCT00733811
- NCT00349453
- NCT00350662
- NCT00530127
- NCT00897221
- NCT00943748
- NCT01539837
- NCT02655315
- NCT02728843
- NCT01146925
- NCT01391520
- NCT01709032
- NCT02083575
- NCT02173951
- NCT01741532
- NCT02174848
- NCT01835496
- NCT02191657
- NCT02456558
- NCT02878538
- NCT03293069
- NCT04184453
- NCT05111821
- NCT05604131
- Dose
- 75 mg/kg/day
- Route
- Oral
- How often
- Twice daily
Conditions of use
- Take with food
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 42.23
- Calculated partition coefficient (ALogP)
- 0.4
- Calculated partition coefficient (XLogP)
- 0.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 10
- Molecular formula
- C7H9NO2
- Monoisotopic mass
- 139.063328530
- Natural product
- Yes
- 0054-0576
- 0054-0711
- 10122-101
- 10122-103
- 10122-104
- 73190-095
- 75907-348
- 75907-349
- 51672-4196
- 51672-4237
- Recorded assays
- 2,070
- Active assays
- 26
- Confirmatory
- Other
- Screening
- Iron Chelating Agents
Distribution coefficient (LogD)
- Median
- -0.3
- Mean
- -0.7575
- Minimum
- -2.6
- Maximum
- 0.17
- Unit
- unitless
- Assays
- 4
- Standard deviation
- 1.30582
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Related records
Trials (91)
- A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers
- A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
- A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
- A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease
- A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment
- A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy
- A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
- A Study Investigating the Long-term Safety and Efficacy of Deferiprone in Patients With Friedreich's Ataxia
- A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia
- A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
- An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients
- An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers
- An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment
- Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects
- Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
- Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration
- Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma
- Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients
- Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients
Approved for (5)
- Beta thalassemia
- Beta-thalassemia major
- Iron overload, susceptibility to
- Sickle cell disease
- Thalassemia
In development for (10)
- Aceruloplasminemia Early phase 1
- Acute kidney injury Phase 3
- Acute myocardial infarction Phase 1
- Amyotrophic lateral sclerosis Phase 2
- Friedreich ataxia Phase 2
- Hereditary hemochromatosis Phase 3
- HIV infectious disease Phase 1
- Pantothenate kinase-associated neurodegeneration Phase 3
- Parkinson disease Phase 2
- Stroke disorder Phase 2
Other linked conditions (1)
- Iron poisoning